No CrossRef data available.
Article contents
Efficacy and toxicity hypofractionated radiotherapy for centrally located non-small cell lung cancer
Published online by Cambridge University Press: 17 May 2021
Abstract
Aim:
Centrally located early-stage non-small cell lung cancer in patients who are unfit for surgery are treated with fractionated radiotherapy. We present the outcomes of a moderately hypofractionated accelerated dose regimen of 50 Gy in 15 fractions from a single centre in the UK.
Materials and methods:
Electronic case notes and radiotherapy records of lung cancer patients treated between January 2014 and December 2016 were retrospectively reviewed. Adult Comorbidity Evaluation-27 score was used to evaluate comorbidities. Mean lung doses and percentage of lung receiving more than 20 Gy were calculated for all patients. Survival outcomes were estimated using Kaplan–Meier curves.
Results:
Fifty-three patients were included in the study; the median follow-up was 20.2 months. 87% of patients had stage I disease. There was no 30-day post-treatment mortality. Ninety-day mortality rate after radiotherapy was 3.8%. Grade 2 pneumonitis was seen in five patients while no grade 3 or 4 pneumonitis was observed. The median progression-free survival (PFS) and overall survival (OS) were 18.5 months and 28.2 months, respectively. The estimated 1 and 2 years PFS were 62.3% and 41.3%, respectively, and OS were 77.4% and 56.6%, respectively. Worsening performance status was associated with worse survival on cox regression analysis. Disease relapsed in 36% of patients. 7.5% of patients with relapsed disease had infield recurrence.
Findings:
50 Gy in 15 fractions radiotherapy for central early-stage lung cancer is a feasible choice that requires further randomised trials.
- Type
- Original Article
- Information
- Copyright
- © The Author(s), 2021. Published by Cambridge University Press
References
http://wclc2017.iaslc.org/wp-content/uploads/2017/09/2017-WCLC-Fact-Sheet-Lung-Cancer-Final.pdf. Accessed on 16th March 2021.Google Scholar
Kennedy, MPT, Cheyne, L, Darby, M et al. Lung cancer stage-shift following a symptom awareness campaign. Thorax 2018; 73 (12): 1128. doi: 10.1136/thoraxjnl-2018-211842.CrossRefGoogle ScholarPubMed
Bansal, S, Okoli, S, Cole, C, Jeannerat, D. Beneficial lung cancer stage-shift: implementation of large scale lung cancer screening program in a community health care system. Chest 2019; 155 (4): 191A. doi: 10.1016/j.chest.2019.02.187.CrossRefGoogle Scholar
Froesch, P, Martucci, F, Györik, S, Dutly, AE, Cafarotti, S. Management of non-small cell lung cancer in the elderly. Eur J Intern Med 2014; 25 (10): 888–894. doi: 10.1016/j.ejim.2014.10.024. Epub 31 October 2014. Review.CrossRefGoogle ScholarPubMed
https://www.nice.org.uk/guidance/cg121/chapter/1-guidance. Accessed on 16th March 2021.Google Scholar
Ball, D, Mai, GT, Vinod, S et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2019; 20 (4): 494–503. doi: 10.1016/S1470-2045(18)30896-9.CrossRefGoogle ScholarPubMed
Timmerman, R, McGarry, R, Yiannoutsos, C et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24: 4833–4839.CrossRefGoogle Scholar
Fakiris, AJ, McGarry, RC, Yiannoutsos, CT et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009; 75: 677–682.CrossRefGoogle ScholarPubMed
Timmerman, R, Mcgarry, R, Yiannoutsos, C et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy in medically inoperable early stage lung cancer. J Clin Oncol 2006; 24: 4833–4839.CrossRefGoogle Scholar
Rowell, N, Williams, C. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev 2001; (1). doi: 10.1002/14651858.CD002935.CrossRefGoogle ScholarPubMed
Faria, SL, Souhami, L, Portelance, L et al. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer. Radiat Oncol 2006; 1: 42.CrossRefGoogle ScholarPubMed
Kong, FM, Ritter, T, Quint, DJ et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys 2011; 81 (5): 1442–1457. doi: 10.1016/j.ijrobp.2010.07.1977.CrossRefGoogle ScholarPubMed
Piccirillo, JF, Creech, CM, Zequeira, R, Anderson, S, Johnston, AS. Inclusion of comorbidity into oncology data registries. J Reg Manag 1999; 26: 66–70.Google Scholar
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed on 16th March 2021.Google Scholar
https://www.rcplondon.ac.uk/projects/outputs/nlca-annual-report-2018. Accessed on 16th March 2021.Google Scholar
Kothary, N, Lock, L, Sze, DY, Hofmann, LV. Computed tomography–guided percutaneous needle biopsy of pulmonary nodules: impact of nodule size on diagnostic accuracy. Clin Lung Cancer 2009; 10 (5): 360–363. doi: 10.3816/CLC.2009.n.049.CrossRefGoogle ScholarPubMed
Heerink, W J, de Bock, G H, de Jonge, G J et al. Complication rates of CT-guided transthoracic lung biopsy: meta-analysis. Eur Radiol 2017; 27 (1): 138–148. doi: 10.1007/s00330-016-4357-8.CrossRefGoogle ScholarPubMed
Prezzano, KM, Ma, SJ, Hermann, GM, Rivers, CI, Gomez-Suescun, JA, Singh, AK. Stereotactic body radiation therapy for non-small cell lung cancer: A review. World J Clin Oncol 2019; 10 (1): 14–27. doi: 10.5306/wjco.v10.i1.14.CrossRefGoogle ScholarPubMed
Bezjak, A, Paulus, R, Gaspar, LE et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non–small-cell lung cancer: NRG oncology/RTOG 0813 trial. JCO 2019; 37 (15): 1316–1325. doi: 10.1200/JCO.18.00622.CrossRefGoogle ScholarPubMed
Iyengar, P, Westover, KD, Court, LE et al. A phase III randomized study of image guided conventional (60 Gy/30 fx) versus accelerated, hypofractionated (60 Gy/15 fx) radiation for poor performance status stage II and III NSCLC patients—an interim analysis. Int J Radiat Oncol Biol Phy 2016; 96 (2): E451. doi: 10.1016/j.ijrobp.2016.06.1763.CrossRefGoogle Scholar
Spencer, KL, Kennedy, MPT, Lummis, KL et al. Surgery or radiotherapy for stage I lung cancer? An intention to treat analysis. Eur Respir J 2019: 1801568. doi: 10.1183/13993003.01568-2018.CrossRefGoogle ScholarPubMed
Guckenberger, M, Allgäuer, M, Appold, S et al. Safety and efficacy of stereotactic body radiotherapy for stage I non–small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 2013; 8 (8): 1050–1058. doi: 10.1097/JTO.0b013e318293dc45.CrossRefGoogle Scholar
Machtay, M, Bae, K, Movsas, B et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2012; 82 (1): 425–434. doi: 10.1016/j.ijrobp.2010.09.004.CrossRefGoogle ScholarPubMed
Rakhsha, A, Azghandi, S, Taghizadeh-Hesary, F. COVID-19 pandemic and patients with cancer: The protocol of a Clinical Oncology center in Tehran, Iran. Rep Pract Oncol Radiother 2020; 25 (5): 765–767, ISSN 1507-1367.CrossRefGoogle ScholarPubMed
Faivre-Finn, C. et al. Reduced fractionation in lung cancer patients treated with curative-intent Radiotherapy during the COVID-19 Pandemic. Clin Oncol 2020; 32 (8): 481–489.CrossRefGoogle ScholarPubMed